Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry.

Autor: Arnold SV; Department of Cardiology, Saint Luke's Mid America Heart Institute and University of Missouri, Kansas City, Missouri., Kosiborod M; Department of Cardiology, Saint Luke's Mid America Heart Institute and University of Missouri, Kansas City, Missouri., Wang J; Department of Cardiology, Saint Luke's Mid America Heart Institute and University of Missouri, Kansas City, Missouri., Fenici P; AstraZeneca, Cambridge, UK., Gannedahl G; AstraZeneca, Gothenburg, Sweden., LoCasale RJ; AstraZeneca, Gaithersburg, Maryland.
Jazyk: angličtina
Zdroj: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Aug; Vol. 20 (8), pp. 2000-2003. Date of Electronic Publication: 2018 Apr 19.
DOI: 10.1111/dom.13303
Abstrakt: We examined the prevalence of cardio-renal-metabolic (CaReMe) conditions and their combinations among 530 747 adults with type 2 diabetes in a USA-based outpatient registry of 271 primary care, cardiology and endocrinology offices. We evaluated the following CaReMe conditions: hypertension, hyperlipidaemia, coronary artery disease (CAD), chronic kidney disease (CKD), cerebrovascular disease, peripheral artery disease, atrial fibrillation, heart failure, and gout or hyperuricaemia; prevalence estimates were adjusted based on the distribution of diabetes by age in the US population in 2015. We found that it was uncommon for patients to have isolated type 2 diabetes without other CaReMe conditions, with only 6.4% having no other CaReMe conditions and 51% having ≥3 other CaReMe conditions. The most prevalent individual conditions were hypertension (83%), hyperlipidemia (81%), CAD (32%) and CKD (20%), and the most common combinations included various groupings of hypertension, hyperlipidaemia, atherosclerotic cardiovascular disease and CKD. Older age, male sex and tobacco use were each associated with increased numbers of CaReMe conditions. These findings highlight the clinical need for novel treatment strategies for diabetes that address both glycaemia and coexisting disease states.
(© 2018 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: